|
编者按：2024年美国临床肿瘤学会（ASCO）年会将于美国东部时间5月31日至6月4日在芝加哥举行。作为全球肿瘤治疗领域规模最大的学术盛会之一，日前，ASCO官网公布了此次年会的日程和摘要题目。肿瘤瞭望将乳腺癌领域重磅研究题目进行了汇总，以飨读者（如有遗漏或错误，请后台留言）。 Rapid Oral Abstract Session Breast Cancer—Local/Regional/Adjuvant 开始时间：2024年5月31日GMT-5（美国东部时间）下午2:45～下午4:15 地点：E451 摘要号：LBA509 Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial. I-SPY2.2研究结果：datopotamab deruxtecan（Dato）新辅助治疗后患者的病理学完全缓解（pCR）率 讲者：Jane Lowe Meisel, MD | Winship Canter Institute of Emory University 报告时间：GMT-5 下午2:45 摘要号：511 Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline. MammaPrint指数与接受化疗联合或不联合蒽环类药物治疗的HR+/HER2-早期乳腺癌患者3年预后的相关性 讲者：Joyce O'Shaughnessy, MD | Baylor University Medical Center, Texas Oncology, The US Oncology Network 报告时间：GMT-5 下午2:51 摘要号：512 Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. NATALEE研究中淋巴结阴性（N0）HR+/HER2-早期乳腺癌（EBC）患者的基线（BL）特征和疗效终点 讲者：Denise A. Yardley, MD | Sarah Cannon Research Institute 报告时间：GMT-5 下午3:09 摘要号：513 The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer. 豁免辅助内分泌治疗（AET）对ER-low（1-10%）早期乳腺癌的影响 讲者：Grace Mei Yee Choong, MD | Mayo Clinic 报告时间：GMT-5 下午3:15 摘要号：514 Oncologic outcome of response-guided axillary treatment in patients with cN1 breast cancer after primary systemic therapy. cN1乳腺癌患者初次全身性治疗后根据疗效指导腋窝治疗的肿瘤学结局 讲者：Annemiek van Hemert, MD | Antoni van Leeuwenhoek / Netherlands Cancer Institute 报告时间：GMT-5 下午3:15 摘要号：515 Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial. RxPONDER研究中不同人种和民族的复发评分、基因轴评分和结局 讲者：Yara Abdou, MD | The University of North Carolina at Chapel Hill 报告时间：GMT-5 下午3:39 摘要号：516 Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial. 在GEICAM/2003-11_CIBOMA/2004-01研究中，由FOXC1表达定义的非基底亚型是卡培他滨治疗三阴性乳腺癌疗效的独立预测因子 讲者：Federico Gustavo Rojo Todo, MD, PhD | Hospital Universitario Fundación Jiménez Díaz; CIBERONC-ISCCIII; GEICAM Spanish Breast Cancer Group 报告时间：GMT-5 下午3:45 摘要号：517 Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort. 在一个多样化乳腺癌队列中，预测性生物标志物MHC-I和MHC-II与临床和分子特征之间的相关性 讲者：Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center 报告时间：GMT-5 下午3:51 Breast Cancer—Metastatic 时间：2024年6月3日GMT-5（美国东部时间）上午11:30～下午1:00 地点：Hall D1 摘要号：1014 Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2. 哌柏西利（palbociclib）、瑞波西利（ribociclib）或阿贝西利（abemaciclib）一线治疗HR+/HER2- aBC患者的抗肿瘤疗效比较：意大利多中心、真实世界研究PALMARES-2的结果 讲者：Claudio Vernieri, MD, PhD, PhD (c) | Fondazione IRCCS INT 报告时间：GMT-5 上午11:30 摘要号：1015 H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). H3B-6545在局部晚期/转移性雌激素受体阳性（ER+）、HER2阴性乳腺癌（BC）女性患者中的应用 讲者：Erika P. Hamilton, MD | Sarah Cannon Research Institute 报告时间：GMT-5 上午11:36 摘要号：1016 Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial. SONIA研究中接受内分泌治疗（±CDK4/6抑制剂）的HR+晚期乳腺癌患者的认知功能 讲者：Maryse Luijendijk, MSc | Psychosocial Research and Epidemiology, Netherlands Cancer Institute 报告时间：GMT-5 上午11:42 摘要号：1017 Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer. ER+/HER2-转移性乳腺癌的基因组特征和靶向治疗使用的种族差异 讲者：Emily L Podany, MD | Washington University in St. Louis 报告时间：GMT-5 下午12:00 摘要号：1018 Genomic and tumor microenvironment dynamics of brain metastases in breast cancer. 乳腺癌脑转移的基因组学和肿瘤微环境动力学 讲者：DHARMINI MANOGNA, MD | Tulane Medical University 报告时间：GMT-5 下午12:06 摘要号：1019 Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer. 分子影像学在新诊断转移性乳腺癌中的临床应用 讲者：Carolina Pia Schroder, MD, PhD | Department of Medical Oncology, Netherlands Cancer Institute 报告时间：GMT-5 下午12:12 摘要号：1020 ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). ACE-Breast-02：比较新型抗HER2抗体-药物偶联物（ADC）ARX788与拉帕替尼联合卡培他滨治疗HER2+晚期乳腺癌（ABC）的关键性2/ 3期试验 讲者：胡夕春 MD, PhD |复旦大学附属肿瘤医院 报告时间：GMT-5 下午12:30 摘要号：1021 TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. 2期TBCRC 048（奥拉帕利扩展）扩展队列：奥拉帕利单药治疗携带PALB2生殖细胞系（g）突变或体细胞BRCA1/BRCA2突变的转移性乳腺癌（MBC）患者 讲者：Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center 报告时间：GMT-5 下午12:36 摘要号：1022 Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy. BRIA-IMT（一种异体全细胞免疫疗法）治疗晚期/转移性乳腺癌（aMBC）的结果 讲者：Carmen Julia Calfa, MD| Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine 报告时间：GMT-5 下午12:42 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 时间：2024年6月3日GMT-5（美国东部时间）上午8:00 ～上午9:30 地点：S406 摘要号：3017 Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41. NSABP B-41研究中，间质肿瘤浸润淋巴细胞（TILs）与接受新辅助化疗和HER2靶向治疗的早期乳腺癌（BC）患者的病理完全缓解（pCR）之间的关系 讲者：Ilana Schlam, MD| Tufts Medical Center 报告时间：GMT-5 上午8：42 Care Delivery/Models of Care 时间：2024年6月3日GMT-5（美国东部时间）上午8:00～上午9:30 地点：S402 摘要号：1518 Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study. 尝试怀孕的年轻乳腺癌幸存者的生育能力：一项前瞻性、多中心队列研究 讲者：Kimia Sorouri, MD, MPH|Dana-Farber Cancer Institute 报告时间：GMT-5 上午8:12 Prevention, Risk Reduction, and Genetics 时间：2024年6月1日GMT-5（美国东部时间）上午8:00～上午9:30 地点：S402 摘要号：10509 The frequency of HER2-low breast cancer among BRCA1, BRCA2, and PALB2 mutation carriers. BRCA1、BRCA2和PALB2突变携带者中HER2-low乳腺癌的发生率 讲者：Lindsay Goldblatt, MD|Hospital of University of Pennsylvania 报告时间：GMT-5 上午8:00 摘要号：10512 Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance. 具有不确定意义的生殖细胞系变异的乳腺癌患者在真实世界中的癌症治疗情况 讲者：Allison W. Kurian, MD, MS, MSc, FASCO|Stanford Cancer Institute, Stanford University School of Medicine 报告时间：GMT-5 上午8:30 Central Nervous System Tumors 时间：2024年6月2日GMT-5（美国东部时间）上午11:30～下午1:00 地点：E350 摘要号：2018 Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. 图卡替尼+曲妥珠单抗+卡培他滨治疗HER2+乳腺癌软脑膜转移：2期TBCRC049的研究结果 讲者：Barbara Jane O'Brien, MD|The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology 报告时间：GMT-5 下午12:12 Oral Abstract Session LBA Session: Presentation and Discussion of LBA1000 时间：2024年6月2日GMT-5 上午7:30～上午8:00 地点：Hall D1 摘要号：LBA1000 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 在既往接受过内分泌治疗（ET）的激素受体阳性（HR+）、人表皮生长因子受体2（HER2）低表达或者超低表达转移性乳腺癌（mBC）患者（pts）中，对比Trastuzumab deruxtecan（T-DXd）与医师选择的化疗（TPC）的效果：DESTINY-Breast06（DB-06）的主要结果。 讲者：Giuseppe Curigliano, MD, PhD |University of Milan and European Institute of Oncology, IRCCS 报告时间：GMT-5 上午7:30 Breast Cancer—Metastatic 时间：2024年6月1日GMT-5（美国东部时间）下午3:00～下午6:00 地点：Hall B1 摘要号：LBA1001 Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. 阿贝西利+氟维司群vs氟维司群单药治疗既往CDK4/6抑制剂联合内分泌经治后出现进展的HR+/HER2-晚期乳腺癌：Ⅲ期postMONARCH研究的主要结局 讲者：Kevin Kalinsky, MD, MS | Winship Cancer Institute of Emory University 报告时间：GMT-5下午3:00 摘要号：LBA1002 Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL. 哌柏西利+依西美坦+GnRH激动剂vs.卡培他滨治疗绝经前HR+/HER2-转移性乳腺癌：随机Ⅱ期Young-PEARL研究生存结果更新 讲者：Yeon Hee Park, MD, PhD | Samsung Medical Center, Sungkyunkwan University 报告时间：GMT-5下午3:12 摘要号：1003 First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. 辅助内分泌完成后12个月内复发的PIK3CA突变、HR+/HER2-局部晚期/转移性乳腺癌患者，一线应用inavolisib/安慰剂+哌柏西利+氟维司群（Inavo/Pbo+Palbo+Fulv）进行治疗：INAVO120 Ⅲ期随机试验额外分析 讲者：Dejan Juric, MD | Medicine-Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center 报告时间：GMT-5 下午3:24 摘要号：LBA1004 SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. SACI-IO HR+：一项随机2期试验，sacituzumab govitecan联用或不联用帕博利珠单抗治疗转移性激素受体阳性/HER2阴性乳腺癌患者。 讲者：Ana Christina Garrido-Castro, MD | Dana-Farber Cancer Institute 报告时间：GMT-5 下午4:00 摘要号：1005 Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202. Enfortumab vedotin（EV）在EV-202研究中三阴性乳腺癌（TNBC）和HR+/HER2-乳腺癌队列中的应用 讲者：Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute 报告时间：GMT-5 下午4:12 摘要号：1006 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. 在既往接受过治疗、不可手术或转移性激素受体阳性、HER2阴性（HR+/HER2-）乳腺癌患者中比较Datopotamab deruxtecan（Dato-DXd）vs化疗（CT）的疗效：TROPION-Breast01研究的患者报告结局（PROs） 讲者：Sonia Pernas, MD, PhD | Institut Català d'Oncologia, IDIBELL, L’Hospitalet 报告时间：GMT-5 下午4:24 摘要号：1007 Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). 曲妥珠单抗和帕妥珠单抗联合甲磺酸艾立布林或紫杉类药物作为HER2阳性、局部晚期或转移性乳腺癌的一线化疗治疗：日本一项多中心、随机、非劣效性3期试验的结果（JBCRG-M06/EMERALD） 讲者：Toshinari Yamashita, MD, PhD | Kanagawa Cancer Center 报告时间：GMT-5 下午5:00 摘要号：1008 Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer. PATRICIA队列C（SOLTI-1303）的主要结果：这是一项随机2期研究，在既往接受过治疗的HER2阳性和PAM50 luminal型晚期乳腺癌患者中评估了哌柏西利联合曲妥珠单抗和内分泌治疗的疗效。 讲者：Eva Ciruelos, MD, PhD | Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre 报告时间：GMT-5 下午5:12 摘要号：1009 DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. DESTINY-Breast07：T-DXd单药治疗和T-DXd +帕妥珠单抗治疗既往未经治疗的HER2+ mBC患者的剂量扩展期中分析 讲者：Fabrice Andre, MD, PhD|Gustave Roussy, Université Paris-Saclay 报告时间：GMT-5 下午5:24 Breast Cancer—Local/Regional/Adjuvant 时间：2024年6月3日GMT-5（美国东部时间）下午3:00～下午6:00 地点：Hall B1 摘要号：LBA500 A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. A-BRAVE研究：阿维鲁单抗治疗新辅助化疗后有残余病变或初次手术和辅助化疗后高危的早期三阴性乳腺癌的3期随机试验 讲者：Pier Franco Conte, MD | Department of Surgery Oncology and Gastroenterology, University of Padua 报告时间：GMT-5 下午3:00 摘要号：LBA501 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial. datopotamab deruxtecan（Dato）联合度伐利尤单抗（Durva）用于新辅助治疗后患者的病理完全缓解率（pCR）：I-SPY2.2研究结果 讲者：Rebecca Arielle Shatsky, MD | University of California, San Diego Medical Center 报告时间：GMT-5 下午3:12 摘要号：LBA502 A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. 一项随机、多中心、开放标签的3期试验，在早期三阴性乳腺癌患者中比较蒽环类药物序贯紫杉烷与蒽环类药物序贯紫杉烷联合卡铂作为（新）辅助治疗：韩国癌症研究组BR 15-1 pearl研究 讲者：Joohyuk Sohn, MD, PhD | Division of Medical Oncology, Yonsei Cancer Center 报告时间：GMT-5 下午3:24 摘要号：LBA503 ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer. ECOG-ACRIN EAZ171：在早期乳腺癌黑人女性中，分析生殖细胞系突变和紫杉烷类型与紫杉烷诱发的周围神经病变（TIPN）的关联 讲者：Tarah Jean Ballinger, MD | Indiana University Simon Comprehensive Cancer Center 报告时间：GMT-5 下午4:00 摘要号：504 Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers. 激素受体状态和肿瘤亚型对年轻BRCA携带者乳腺癌临床行为和预后的影响 讲者：Luca Arecco, MD | Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy and Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB) 报告时间：GMT-5 下午4:12 摘要号：505 Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). 在SWOG S1007（RxPONDER）研究中，血清抗苗勒氏管激素（AMH）水平与鉴别最有可能从辅助化疗中获益的绝经前激素受体阳性（HR+）、her2阴性、淋巴结阳性乳腺癌患者之间的相关性 讲者：Kevin Kalinsky, MD, MS | Winship Cancer Institute, Emory University 报告时间：GMT-5 下午4:24 摘要号：506 Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. 阐明HR+/HER2- MammaPrint High 2早期乳腺癌的免疫活性状态 讲者：Erin Frances Cobain, MD|University of Michigan 报告时间：GMT-5 下午5:00 摘要号：LBA507 Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). 在abemaciclib联合内分泌治疗（ET）治疗HR+、HER2-、淋巴结阳性、高危早期乳腺癌（EBC）辅助治疗的monarchE试验中，ctDNA检测在预后中的作用 讲者：Sherene Loi, MD, PhD|Peter MacCallum Cancer Centre 报告时间：GMT-5 下午5:12 摘要号：508 Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer. RSClin N+工具用于激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-）、淋巴结阳性乳腺癌的开发与验证 讲者：Lajos Pusztai, MD, PhD, FASCO, D.Phil|Yale University Cancer Center 报告时间：GMT-5 下午5:36 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 时间：2024年6月1日GMT-5下午3:00～下午6:00 地点：Hall D1 摘要号：3006 A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer. 首创新药KAT6抑制剂（PF-07248144）在晚期或转移性ER+ HER2-乳腺癌患者中开展的1期剂量扩展研究 讲者：Patricia LoRusso, DO, PhD, FASCO|Yale University Cancer Center 报告时间：GMT-5 下午4:24 Care Delivery and Quality Care 时间：2024年5月31日GMT-5（美国东部时间）下午2:45～下午5:45 地点：S100a 摘要号：11007 Early integrated rehabilitation and vocational rehabilitation in 435 patients with breast cancer: A comparison between the intervention group and control group in a prospective study. 435例乳腺癌患者早期综合康复和职业康复的前瞻性研究：干预组与对照组的比较 讲者：Nikola Besic, MD|Institute of Oncology Ljubljana 报告时间：GMT-5下午4:57 Care Delivery and Quality Care 时间：2024年6月4日GMT-5上午9:45～下午12:45 地点：S100bc 摘要号：1504 A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study). 在转移性乳腺癌患者中比较trastuzumab deruxtecan治疗期间患者电子报告结局（ePRO）监测和常规随访的随机研究（PRO-DUCE研究）。 讲者：Yuichiro Kikawa, MD, PhD|Department of Breast Surgery, Kansai Medical University Hospital 报告时间：GMT-5上午10:57 摘要号：1505 Evaluation of a complex survivorship intervention incorporating electronic patient-reported outcomes in early stage breast and gynecologic cancer: Results from the Linking You to Support and Advice (LYSA) randomized controlled trial. 在早期乳腺癌和妇科癌症中，对包含患者电子报告结局的复杂生存干预措施进行评估：来自LYSA随机对照试验的结果 讲者：Kate O'Connell|BSc in Nursing Studies;RGN; PGDip in Oncology Nursing; PGDip in Applied Health and Wellness Coaching ；Cork University Hospital 报告时间：GMT-5 上午11:09 Prevention, Risk Reduction, and Genetics 时间：2024年6月1日GMT-5下午3:00～下午6:00 地点：S100a 摘要号：10501 Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women. 评价多基因风险评分作为黑人女性早发性三阴性乳腺癌的预测因素 讲者：Holly Jane Pederson, MD|Cleveland Clinic 报告时间：GMT-5 下午3:12 摘要号：10502 Breast cancer polygenic risk score and patient survival outcomes in the Pathways study. Pathways研究中乳腺癌多基因风险评分和患者生存结局 讲者：Arya Mariam Roy, MD|Roswell Park Comprehensive Cancer Center 报告时间：GMT-5 下午3:24 摘要号：10503 Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study. 年轻BRCA携带者乳腺癌的临床行为和基因检测时机对预后的影响：来自一项国际队列研究的结果 讲者：Matteo Lambertini, MD|IRCCS Ospedale Policlinico San Martino-University of Genova 报告时间：GMT-5 下午4:00 Symptom Science and Palliative Care 时间：2024年6月2日GMT-5 上午8:00～上午11:00 地点：S100a 摘要号：12008 Walking dose required to achieve a clinically meaningful reduction in cancer-related fatigue among patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide prospective cohort study. 在接受化疗的乳腺癌患者中，达到有临床意义的癌症导致疲乏减少所需的步行剂量：URCC NCORP全国性前瞻性队列研究 讲者：Lindsey Jean Mattick, PhD|James P. Wilmot Cancer Center, University of Rochester Medical Center 报告时间：GMT-5 上午10:24 （ （来源：《肿瘤瞭望》编辑部） |
|
|
来自： 温医一院刘海光 > 《2024 ASCO》
